Luye Pharma Group's Total Assets for the quarter that ended in Dec. 2023 was HK$27,881 Mil.
During the past 12 months, Luye Pharma Group's average Total Assets Growth Rate was 7.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 0.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 4.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 19.80% per year.
During the past 13 years, Luye Pharma Group's highest 3-Year average Total Assets Growth Rate was 64.90%. The lowest was 0.90%. And the median was 29.80%.
The historical data trend for Luye Pharma Group's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Luye Pharma Group's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (HKSE:02186) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Luye Pharma Group's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Luye Pharma Group Total Assets Related Terms
Thank you for viewing the detailed overview of Luye Pharma Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Luye Pharma Group (HKSE:02186) Business Description
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02186 has been successfully added to your 